NCT03368820

Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry

Cardiovascular Morbidities and Lung Cancer Treatment

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: European Lung Cancer Working Party · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Therapeutic algorithms for lung cancer are mainly based on randomised controlled trials which excluded patients with severe co-morbidities. Smoking, the main risk factor for lung cancer, is associated with cardiovascular events that may impact on the therapeutic decision. The aim of this registry is to determine if and how cardiovascular co-morbidities impact on the physicians' decision for anticancer treatment in lung cancer patients by comparing it to the European Lung Cancer Working Party (ELCWP) guidelines

Conditions

• Lung Neoplasm

Interventions

Type	Name	Description
OTHER	No intervention	Treatment left at the discretion of the participant

Timeline

• Start date: 2017-12-04
• Primary completion: 2022-12-31
• Completion: 2023-12-31
• First posted: 2017-12-11
• Last updated: 2021-08-23

Locations

6 sites across 1 country: Belgium